Liraglutide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Liraglutide |
| DrugBank ID | DB06655 |
| Brand Names (EU) | Saxenda, Xultophy |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 96.12% |
Approved Indication (EMA)
Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | opsismodysplasia | 96.12% | DL |
| 2 | thiamine-responsive dysfunction syndrome | 95.64% | DL |
| 3 | focal stiff limb syndrome | 95.26% | DL |
| 4 | classic stiff person syndrome | 95.26% | DL |
| 5 | diabetes mellitus (disease) | 95.08% | DL |
| 6 | autoimmune oophoritis | 93.06% | DL |
| 7 | type 1 diabetes mellitus | 92.27% | DL |
| 8 | drug-induced localized lipodystrophy | 92.19% | DL |
| 9 | centrifugal lipodystrophy | 91.87% | DL |
| 10 | pressure-induced localized lipoatrophy | 91.68% | DL |
| 11 | idiopathic localized lipodystrophy | 91.27% | DL |
| 12 | pancreatic agenesis | 90.44% | DL |
| 13 | cholangiocarcinoma, susceptibility to | 65.21% | DL |
| 14 | atrial flutter (disease) | 64.09% | DL |
| 15 | congenital temporomandibular joint ankylosis | 63.13% | DL |
| 16 | hemoglobin C-beta-thalassemia syndrome | 62.69% | DL |
| 17 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 61.43% | DL |
| 18 | woolly hair, autosomal recessive 3 | 61.35% | DL |
| 19 | mitral valve prolapse, myxomatous | 61.12% | DL |
| 20 | anuria | 60.72% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.